Cerebral Therapeutics Names Julie Foster as Chief Operating Officer
25 Jan 2023
Executive Change
Strategic Appointment to Guide Business Operations, Growth and Portfolio Scalability
AURORA, Colo.--(BUSINESS WIRE)-- Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today the appointment of MedTech industry veteran Julie Foster as Chief Operating Officer. Julie succeeds John Foster who served as Cerebral Therapeutic’s President and COO since 2019, who will move into a business advisor role for the company.
Julie Foster is a seasoned leader with over 30 years of experience at Medtronic. She held positions of increasing responsibility across functional, regional, and general management roles. Most recently as VP of Customer Experience at Diabetes, VP of the Cardiac and Vascular businesses in EMEA, and General Manager of Pain Therapies and Targeted Drug Delivery business in Neuromodulation. She has a reputation as a strategic thought leader with strong business acumen who drives a customer focused, performance-driven culture, and leads business model innovation and change. Julie’s broad base of experience includes general management, global marketing, commercial operations, channel optimization, navigating complex regulatory and reimbursement requirements, and building diverse, high performing teams.
As the new COO, Julie Foster will lead and scale the company’s growth and business operations, reporting to Dan Abrams, M.D., Chief Executive Officer of Cerebral Therapeutics. “Julie is a versatile leader who has demonstrated leadership in successfully developing and commercializing therapies for patients with serious unmet medical needs,” said Abrams. “Her impressive track record of empowering diverse teams to perform at their best to develop and launch new products and therapies will be key as we advance our portfolio starting with CT-010, our program for patients with severe medically refractory epilepsy. In addition, I would like to thank John Foster for his important contributions to the business over the last three plus years which enabled us to achieve our critical milestones, to advance our mission, and to grow as an organization.”
“It is a privilege to join this team of industry experts to advance Cerebral Therapeutics' mission to improve the lives of patients suffering from severe neurological diseases for whom oral medicines are not effective or are limited by systemic side effects,” added Julie. “The unique approach and focus on the intracerebroventricular (ICV) route of administration has the potential to make a meaningful impact in the lives of many patients. The company’s strategy to develop, in-license, and co-develop new drug therapies using its proprietary ICV technology is groundbreaking and I’m pleased to help advance this meaningful work.”
About Cerebral Therapeutics
Cerebral Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for refractory neurological diseases. Founded by experts in the fields of neuroscience, neurosurgery, and drug delivery, the Company is pioneering intracerebroventricular (ICV) therapies for people with neurological diseases. Its investigational drug therapies and companion biomarker strategies are enabled by the Company’s proprietary technology that enables precise targeted delivery to the central nervous system. The goal of this novel approach is to maximize efficacy while greatly reducing systemic drug exposure and enhancing drug regimen compliance. Cerebral Therapeutics’ ICV infusion therapy may offer a more efficacious and reliable approach to treating neurological diseases for which oral medications are not able to achieve adequate control and/or are limited by systemic toxicities.
For more information visit .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.